Last reviewed · How we verify
Arm 1: IL13Ra2-specific CAR Tcm cells
At a glance
| Generic name | Arm 1: IL13Ra2-specific CAR Tcm cells |
|---|---|
| Also known as | Autologous IL13(EQ)BBzeta/CD19t+ Tcm-enriched T Cells, IL13Ra2-CAR/CD19t+ Tcm |
| Sponsor | City of Hope Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: